EMA to begin evaluation of Russia’s Sputnik V Covid vaccine

h 56271338

Europe’s medicines watchdog, specifically the European Medicines Agency (EMA) on Thursday stated it would begin reviewing the Russian-made Sputnik V vaccine for Coronavirus, 

The resolution by EMA’s human medicines committee (CHMP) “is based on results from laboratory studies and clinical studies in adults. These studies indicate that Sputnik V triggers the production of antibodies and immune cells that target the SARS-CoV-2 coronavirus and may help protect against COVID-19,” the Amsterdam-based company stated in a assertion.

“EMA will assess Sputnik V’s compliance with the usual EU standards for effectiveness, safety and quality. While EMA cannot predict the overall timelines, it should take less time than normal to evaluate an eventual application because of the work done during the rolling review,” the medicines watchdog added. 

The jab, developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology has already been imported in a number of EU nations, regardless of frequent warnings by the Commission towards undermining the belief in vaccines. 

The announcement got here days after Slovakia turned the second member-state after Hungary to obtain deliveries of Sputnik V, bypassing the EU drug regulator.